Rozlytrek, Roche’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
The European Commission has granted conditional marketing authorisation for…
Novartis announces FDA approval of MET inhibitor Tabrecta (capmatinib)for metastatic non-small cell lung cancer with METex14
Novartis has announced that the US Food and Drug Administration (FDA) approved…